Correlation between serum level of miRNA-106a expression with clinicopathological characteristics and prognosis of patients with renal cell carcinoma.
10.3760/cma.j.cn511374-20200430-00317
- Author:
Qingyan YANG
1
;
Junyi LIU
;
Yalin LIANG
;
Changan WANG
;
Jianle HAN
;
Litao ZHU
;
Shengping YUAN
;
Qiang SUN
;
Hongsen ZHANG
Author Information
1. Department of Kidney Transplantation and Nephrology, Zhengzhou Seventh People's Hospital, Zhengzhou, Henan 450016, China. zhanyanlw@126.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor/genetics*;
Carcinoma, Renal Cell/genetics*;
Gene Expression Regulation, Neoplastic;
Humans;
Kidney Neoplasms/genetics*;
MicroRNAs/genetics*;
Neoplasm Recurrence, Local;
Prognosis
- From:
Chinese Journal of Medical Genetics
2021;38(7):652-655
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the expression of microRNA-106a(miR-106a) in renal cell carcinoma (RCC) and its correlation with clinicopathological characteristics and prognosis of patients.
METHODS:Serum samples of 64 patients with newly diagnosed RCC were collected as the study group, and serum samples of 40 healthy individuals were used as the control group. Real-time fluorescence quantitative PCR was used to determine the expression level of miR-106a in each group. The correlation between miR-106a expression and clinicopathological characteristics of the patients was studied with single factor analysis and multiple Logistic regression model. Kaplan-Meier survival curve was used to analyze its correlation with the prognosis of patients.
RESULTS:Before surgery, compared with the control group (1.17± 0.58), RCC patients with high- (9.15± 0.96) and low-expression(3.45± 0.37) had increased expression of miR-106a. Postoperatively, the expression level of miR-106a in both groups of patients decreased to 1.53± 0.18 and 1.75± 0.21, respectively. The area under the curve (AUC) of the diagnostic value of serum miR-106a for RCC was 0.782 (95% CI: 0.661-0.902). With an optimal cutoff value of 0.531, the sensitivity was 78.10% and the specificity was 75.00%. Serum miR-106a level of RCC patients with TNM stage T3 or T4, clinical stage II or III, lymph node metastasis, and recurrence were significantly increased. The high expression of serum miR-106a in RCC patients has an independent relationship with the tumor TNM stage and lymph node metastasis. Of the 64 follow-up patients, 4 were lost and 30 had died. Among them, the median survival time of patients in the miR-106a high expression group was 30 months, which was significantly shorter than that of the low expression group (52 months).
CONCLUSION:The serum level of miR-106a is elevated in RCC patients, and may be used as a molecular marker for the diagnosis of RCC. High serum expression of miR-106a is an independent predictor for tumor TNM stage and lymph node metastasis, as well as an independent predictor for poor prognosis of RCC patients.
